Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Marcus Horstmann, Oliver Patschan, Jörg Hennenlotter, Erika Senger, Gerhard Feil & Arnulf Stenzl. (2009) Combinations of urine-based tumour markers in bladder cancer surveillance. Scandinavian Journal of Urology and Nephrology 43:6, pages 461-466.
Read now
Read now
Articles from other publishers (15)
Jing Xu, Danielle E Westfall & Jean R Lopategui. (2021) “Indeterminate” UroVysion Fluorescence In Situ Hybridization Results. American Journal of Clinical Pathology.
Crossref
Crossref
Rui Batista, João Vinagre, Hugo Prazeres, Cristina Sampaio, Pedro Peralta, Paulo Conceição, Amílcar Sismeiro, Ricardo Leão, Andreia Gomes, Frederico Furriel, Carlos Oliveira, João Nuno Torres, Pedro Eufrásio, Paulo Azinhais, Fábio Almeida, Edwin Romero Gonzalez, Bohdan Bidovanets, Thorsten Ecke, Pascal Stinjs, Álvaro Serrano Pascual, Rabehi Abdelmalek, Ainara Villafruela, Pastora Beardo-Villar, Nuno Fidalgo, Hakan Öztürk, Carmen Gonzalez-Enguita, Juan Monzo, Tomé Lopes, Mario Álvarez-Maestro, Patricia Parra Servan, Santiago Moreno Perez De La Cruz, Mario Pual Sanchez Perez, Valdemar Máximo & Paula Soares. (2019) Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. Frontiers in Genetics 10.
Crossref
Crossref
Willemien Beukers, Kirstin A. van der Keur, Raju Kandimalla, Yvonne Vergouwe, Ewout W. Steyerberg, Joost L. Boormans, Jorgen B. Jensen, José A. Lorente, Francisco X. Real, Ulrike Segersten, Torben F. Orntoft, Nuria Malats, Per-Uno Malmström, Lars Dyrskjot & Ellen C. Zwarthoff. (2017)
FGFR3
,
TERT
and
OTX1
as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study
. Journal of Urology 197:6, pages 1410-1418.
Crossref
Crossref
Raju Kandimalla, Roy Masius, Willemien Beukers, Chris H. Bangma, Torben F. Orntoft, Lars Dyrskjot, Nikki van Leeuwen, Hester Lingsma, Angela A.G. van Tilborg & Ellen C. Zwarthoff. (2013)
A 3-Plex Methylation Assay Combined with the
FGFR3
Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
. Clinical Cancer Research 19:17, pages 4760-4769.
Crossref
Crossref
Tahlita C.M. Zuiverloon, Willemien Beukers, Kirstin A. van der Keur, Annemieke J.M. Nieuweboer, Thomas Reinert, Lars Dyrskjot, Torben F. Orntoft & Ellen C. Zwarthoff. (2013) Combinations of Urinary Biomarkers for Surveillance of Patients with Incident Nonmuscle Invasive Bladder Cancer: The European FP7 UROMOL Project. Journal of Urology 189:5, pages 1945-1951.
Crossref
Crossref
Kim E.M. van Kessel, Lucie C. Kompier, Esther W. de Bekker-Grob, Tahlita C.M. Zuiverloon, Yvonne Vergouwe, Ellen C. Zwarthoff & Ewout W. Steyerberg. (2013)
FGFR3
Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies
. Journal of Urology 189:5, pages 1676-1681.
Crossref
Crossref
S Miah, E Dudziec, R M Drayton, A R Zlotta, S L Morgan, D J Rosario, F C Hamdy & J W F Catto. (2012) An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. British Journal of Cancer 107:1, pages 123-128.
Crossref
Crossref
Enis Coskuner, Ibrahim Cevik, Alp Ozkan, Ozdal Dillioglugil & Atıf Akdas. (2012) In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors. International Urology and Nephrology 44:3, pages 793-798.
Crossref
Crossref
David P. WoodJr.Jr.. 2012. Campbell-Walsh Urology. Campbell-Walsh Urology
2309
2334.e6
.
Mark L. Gonzalgo & Alan Keith Meeker. 2012. Campbell-Walsh Urology. Campbell-Walsh Urology
530
567.e16
.
Lucie C. Kompier, Irene Lurkin, Madelon N. M. van der Aa, Bas W. G. van Rhijn, Theo H. van der Kwast & Ellen C. Zwarthoff. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy. PLoS ONE 5:11, pages e13821.
Crossref
Crossref
C. Protzel & O.W. Hakenberg. (2010) Molekulare Marker in Diagnostik und Therapie des UrothelkarzinomsMolecular markers in the diagnostics and therapy of urothelial cancer. Der Urologe 49:11, pages 1415-1424.
Crossref
Crossref
Victoria L. Robinson, Michael Porter, Edward Messing, Yves Fradet, Ashish M. Kamat & Yair Lotan. (2010) BCAN Think Tank session 2: Molecular detection of bladder cancer: The path to progress. Urologic Oncology: Seminars and Original Investigations 28:3, pages 334-337.
Crossref
Crossref
Lucie C. Kompier, Angela A.G. van Tilborg & Ellen C. Zwarthoff. (2010) Bladder cancer: Novel molecular characteristics, diagnostic, and therapeutic implications. Urologic Oncology: Seminars and Original Investigations 28:1, pages 91-96.
Crossref
Crossref
Bas W.G. van Rhijn, Henk G. van der Poel & Theo H. van der Kwast. (2009) Cytology and Urinary Markers for the Diagnosis of Bladder Cancer. European Urology Supplements 8:7, pages 536-541.
Crossref
Crossref